-
Turk Kardiyoloji Dernegi Arsivi : Turk... Mar 2022Percutaneous transluminal angioplasty has gained increasing popularity in the treatment of peripheral artery disease. However, the increase in the frequency of this...
Percutaneous transluminal angioplasty has gained increasing popularity in the treatment of peripheral artery disease. However, the increase in the frequency of this procedure also increases the risk of complications. Percutaneous transluminal angioplasty has serious and general complications in terms of device and technique at puncture and dilatation sites. In this case, we describe the easy and practical management of deflating an undeflated ballon in the right superficial femoral artery.
Topics: Angioplasty; Angioplasty, Balloon; Femoral Artery; Humans; Peripheral Arterial Disease; Punctures
PubMed: 35400638
DOI: 10.5543/tkda.2022.21129 -
Circulation. Cardiovascular... Feb 2020
Topics: Angioplasty, Balloon, Coronary; Drug-Eluting Stents; Percutaneous Coronary Intervention; Prognosis
PubMed: 32069104
DOI: 10.1161/CIRCINTERVENTIONS.120.008919 -
JACC. Cardiovascular Interventions Mar 2022
Topics: Angioplasty, Balloon; Arteries; Humans; Treatment Outcome
PubMed: 35272780
DOI: 10.1016/j.jcin.2022.01.304 -
Cardiovascular and Interventional... Oct 2022
Topics: Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Humans; Renal Dialysis; Treatment Outcome
PubMed: 36076110
DOI: 10.1007/s00270-022-03256-2 -
Cardiovascular Revascularization... Oct 2022
Topics: Angioplasty, Balloon, Coronary; Heart Injuries; Humans
PubMed: 35864000
DOI: 10.1016/j.carrev.2022.07.006 -
Current Problems in Cardiology May 2024Pulmonary endarterectomy (PEA) is the first-line treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, some patients with CTEPH are... (Review)
Review
Pulmonary endarterectomy (PEA) is the first-line treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, some patients with CTEPH are considered inoperable, and in the last decade, balloon pulmonary angioplasty (BPA) has emerged as a viable therapeutic option for these patients with prohibitive surgical risk or recurrent pulmonary hypertension following PEA. Numerous international centers have increased their procedural volume of BPA and have reported improvements in pulmonary hemodynamics, patient functional class and right ventricular function. Randomized controlled trials have also demonstrated similar findings. Recent refinements in procedural technique, increased operator experience and advancements in procedural technology have facilitated marked reduction in the risk of complications following BPA. Current guidelines recommend BPA for patients with inoperable CTEPH and persistent pulmonary hypertension following PEA. The pulmonary arterial endothelium plays a vital role in the pathophysiologic development and progression of CTEPH.
Topics: Humans; Angioplasty, Balloon; Chronic Disease; Hypertension, Pulmonary; Pulmonary Artery; Randomized Controlled Trials as Topic
PubMed: 38401824
DOI: 10.1016/j.cpcardiol.2024.102481 -
Journal of the American College of... Mar 2021
Topics: Angioplasty, Balloon, Coronary; Coronary Restenosis; Humans
PubMed: 33663734
DOI: 10.1016/j.jacc.2021.01.005 -
Journal of Vascular Surgery Apr 2020To evaluate the safety and effectiveness of infrainguinal artery revascularization via atherectomy supplemented with other endovascular techniques in an office...
OBJECTIVE
To evaluate the safety and effectiveness of infrainguinal artery revascularization via atherectomy supplemented with other endovascular techniques in an office endovascular center (OEC) setting.
METHODS
A retrospective study was conducted examining 352 lower extremity atherectomy revascularization procedures between 2011 and 2016 at an OEC by five board-certified vascular surgeons. Patients received laser atherectomy or orbital atherectomy followed by angioplasty or angioplasty and stent placement as needed. Reintervention was indicated based on evidence of clinical symptoms and imaging studies. Demographics, vessel-specific data, treatment information, and outcome of procedures were recorded. Data analysis was carried out using Kaplan-Meier survival curves.
RESULTS
Lower extremity atherectomy was carried out in 282 patients in 352 limbs with average age of 69 ± 11 years. Technical success of <30% residual stenosis by angiogram was achieved in 571/594 vessels treated. Within 30 days of procedure, 23/352 limbs required major amputation resulting from pre-existing disease, ranging from 3 Rutherford class 4, 17 Rutherford class 5, to 3 Rutherford class 6 limbs. No 30-day mortality was noted. The primary patency of the 571 treated vessels at 12 months was 90%, and 84% at 29 months. The patency of treated vessels that reached >50% stenosis on follow-up and required reintervention (51/571 vessels) or did not require reintervention (79/571) was 72% and 87% at 23 months' follow-up, respectively, with no difference in risk of occlusion identified (P = .181). There was a significantly increased risk of occlusion for vessels treated with laser atherectomy as compared with orbital atherectomy (odds ratio, 2.552; 95% confidence interval, 1.375-4.735; P = .003). No significant difference in risk of occlusion was found between treatment with atherectomy and angioplasty (466/571 vessels) compared with atherectomy, angioplasty, and stenting (102/571) with secondary patency of 90% and 85% at 6 months' follow-up, respectively. There was no difference in patency between claudicants and patients with critical limb ischemia.
CONCLUSIONS
Atherectomy in conjunction with angioplasty and/or stenting has satisfactory patency with minimal complications when the procedure is carried out in an OEC. Asymptomatic >50% restenosis of treated vessels does not warrant reintervention unless the patient presents with clinical symptoms. Various atherectomy devices may result in different outcomes.
Topics: Aged; Amputation, Surgical; Angioplasty; Atherectomy; Female; Humans; Ischemia; Lower Extremity; Male; Retrospective Studies; Stents; Tibial Arteries; Vascular Patency
PubMed: 31519512
DOI: 10.1016/j.jvs.2019.06.198 -
Cardiovascular Journal of AfricaThe aim was to assess the safety and efficacy of rotational atherectomy followed by drug-eluting balloon (DEB) in patients with a high risk of bleeding.
AIM
The aim was to assess the safety and efficacy of rotational atherectomy followed by drug-eluting balloon (DEB) in patients with a high risk of bleeding.
METHODS
A retrospective review was carried out of hospital records of consecutive patients who underwent the hybrid procedure.
RESULTS
The average age of the 23 patients was 74 years. Risk factors for bleeding included renal failure (35%), oral anticoagulation use (26%) and peptic ulcer disease (35%). All patients had procedural success. No bleeding was reported over the 24-month follow-up period. Dual antiplatelet therapy was stopped successfully in six patients (26%) at three months. Two patients had confirmed target-lesion failure (restenosis). Two patients died over the study period but the cause of death was not known to be cardiovascular disease related.
CONCLUSIONS
For patients at high risk of bleeding who require rotablation, the use of a drug-eluting balloon may be a safe, effective alternative.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Atherectomy; Atherectomy, Coronary; Coronary Angiography; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome
PubMed: 33179716
DOI: 10.5830/CVJA-2020-050 -
Annals of Vascular Surgery Feb 2023The study aimed to assess the 24-month safety and effectiveness of a new generation drug-coated balloon (DCB) (Elutax; AR Baltic Medical, Vilnius Lithuania-also marketed...
BACKGROUND
The study aimed to assess the 24-month safety and effectiveness of a new generation drug-coated balloon (DCB) (Elutax; AR Baltic Medical, Vilnius Lithuania-also marketed as Emperor in some European countries; Aachen Resonance, Germany, and AB Medica, Italy) for the treatment of patients with femoropopliteal lesions.
METHODS
From January 2019 to January 2020, DCB angioplasties using Elutax were performed on 53 consecutive patients (53 limbs) with femoropopliteal lesions (group A) and compared with a noncontemporary control group (group B) consisting of 71 patients (71 limbs) treated with plain old balloon angioplasty (POBA) between January 2017 and January 2018. Before performing the angioplasty, both groups underwent clinical examination, ultrasound evaluation, and computed tomography angiography to delineate subject clinical and baseline lesion characteristics. Primary end point was primary patency rate at 24 months. Secondary end points included clinically driven target lesion revascularization (CD-TLR), overall survival and limb salvage rates.
RESULTS
In both groups technical success rate was 100% with bailout stenting performed in 16.9% (9/53) of lesions in group A, while stenting was necessary in 22.5% of lesions (16/71) in group B. Patients treated with Elutax exhibited lower 24-month restenosis/reocclusion rate and improved primary patency compared to those treated with POBA (restenosis/reocclusion rate: 9.4% vs. 25.3%, CI 95% 0.01-0.30, P = 0.034; primary patency: 88.2% vs. 71.5%, log rank P = 0.03). Twenty-four-month CD-TLR rate was 7.5% for DCB versus 18.3% for POBA. No device or procedure-related deaths occurred, and no 30-day mortality was observed in either group. During the follow-up period, the limb salvage rate was 94.9% for A group and 92.1% for B group. All minor amputations occurred in limbs presented with chronic limb threatening ischemia (CLTI). Overall survival was 91.7% for group A and 89.4% for group B.
CONCLUSIONS
Paclitaxel + Dextran DCB angioplasty proved safe and effective in managing chronic lesions of femoropopliteal arteries. Our experience has shown superior primary patency rate for Elutax when compared to POBA.
Topics: Humans; Popliteal Artery; Peripheral Arterial Disease; Treatment Outcome; Femoral Artery; Angioplasty, Balloon
PubMed: 36374662
DOI: 10.1016/j.avsg.2022.09.047